Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.6552W HIGH $13.25
Volume
136.44 K
Value Traded
3.43 M
Short % Float
1.81%
-6.85%Week
-18.07%1 Month
-4.58%3 Month
+58.88%6 Month
+44.33%5 Year
+688.02%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
357.59 M
EPS (TTM)
-0.09
P/E Ratio
-
Ent. Value
316.35 M
Total Shares
35.06 M
Float Shares
30.12 M
Insiders
14.11%
Institutions
54.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FENC Catalyst Timeline
Dated clinical, regulatory and corporate events for Fennec Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fennec Pharmaceuticals Inc.
499Total events
4Upcoming
123Tier-1 (high impact)
2005 to 2026Coverage
Upcoming catalysts 2
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 50
▲Primary Endpoint MetPedmarkApprovedClinical Data
STS-J01 primary endpoint met: ASHA-defined hearing loss 24.0% vs 56.4% benchmark
cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumorssource ↗
▲Oral PresentationPedmarkApprovedPresentation
Oral presentation of detailed STS-J01 Phase 2 results at 58th SIOP Annual Meeting
cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumorssource ↗
▲Secondary Endpoint DataPedmarkApprovedClinical Data
STS-J01 secondary/exploratory data: 84% Grade 0 hearing loss by Brock; 95.8% objective response rate
cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumorssource ↗
▲PK PD DataPedmarkApprovedClinical Data
STS-J01 prospective PK analyses support six-hour PEDMARK administration interval
cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumorssource ↗
▲Safety Data UpdatePedmarkApprovedClinical Data
STS-J01 safety data: no serious adverse event attributed to PEDMARK
cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumorssource ↗
▲Full ResultsPedmarkApprovedClinical Data
Detailed STS-J01 results: 84% Grade 0 hearing loss by Brock, 95.8% objective response, PK analyses
cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumorssource ↗
◆Poster PresentationPedmarkApprovedPresentation
Poster: Effects of Delayed Sodium Thiosulfate on Cisplatin-Induced Ototoxicity
cisplatin-induced ototoxicitysource ↗
◆Poster PresentationPedmarkApprovedPresentation
Poster: Randomized Phase 1 Trial of Cisplatin-Based Chemotherapy With or Without Sodium Thiosulfate for GCT
metastatic germ cell tumorsource ↗
◆AbstractPedmarkApprovedPresentation
Four abstracts evaluating PEDMARK accepted for 2026 ASCO Annual Meeting
◆Oral PresentationPedmarkApprovedPresentation
Presentation of trial design for randomized Phase 1 study of cisplatin-based chemotherapy with or without sodium thiosulfate (PEDMARK) for men with metastatic germ cell tumor at ASCO 2026
metastatic germ cell tumorsource ↗
◆Poster PresentationPedmarkApprovedPresentation
Poster presentation of audiometric outcomes for IV sodium thiosulfate for CIO prevention in adults with head and neck cancer at ASCO 2026
head and neck cancersource ↗
◆AbstractPedmarkApprovedPresentation
Abstract-only publication: Audiometric Outcomes for Intravenous Sodium Thiosulfate in Head and Neck Cancer
cisplatin-induced ototoxicitysource ↗
▲Primary Endpoint MetPedmarkApprovedClinical Data
STS-J01 trial met primary endpoint with significant reduction in hearing loss
pediatric and AYA non-metastatic solid tumorssource ↗
●Oral PresentationPresentation
Management to host one-on-one investor meetings at Piper Sandler Spring Biopharma Symposium
▲Trial InitiationPedmarkApprovedTrial
University of Arizona Cancer Center initiates investigator-sponsored study of PEDMARK in AYA and adult patients with solid tumors receiving cisplatin
head and neck and testicular cancerssource ↗
▲Trial InitiationPedmarkApprovedTrial
Initiation of third institution-led clinical study evaluating PEDMARK in AYA and adult patients with head and neck and testicular cancers
head and neck and testicular cancerssource ↗
▲Hatch Waxman LitigationPedmarkApprovedIP / Competition
Settlement agreement with Cipla resolving PEDMARK patent litigation
ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumorssource ↗
◆Trial InitiationPedmarkApprovedTrial
Tampa General Hospital Cancer Institute initiates real-world study of PEDMARK in AYA and adult patients
reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatmentsource ↗
▲Trial InitiationPedmarkApprovedTrial
Tampa General Hospital Cancer Institute initiated study evaluating real-world clinical utility of PEDMARK in reducing ototoxicity in AYA and adult cancer patients
AYA and adult cancersource ↗
◆Poster PresentationPedmarkApprovedPresentation
Real world data poster presentation at 2026 Multidisciplinary Head and Neck Cancers Symposium
head and neck cancerssource ↗
▲Oral PresentationPedmarkApprovedPresentation
Presented new real-world data in adults with head and neck cancer at 2026 Multidisciplinary Head and Neck Cancers Symposium
head and neck cancersource ↗
▲Trial InitiationPedmarkApprovedTrial
Trial opened to accrual for randomized Phase 1 study of cisplatin-based chemotherapy with or without sodium thiosulfate for men with metastatic germ cell tumor
metastatic germ cell tumorsource ↗
◆Trial InitiationPedmarkApprovedTrial
Planned initiation of investigator-sponsored study by City of Hope to evaluate PEDMARK for reducing ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors
metastatic testicular germ cell tumorssource ↗
◆Oral PresentationPresentation
Fireside chat at Piper Sandler 37th Annual Healthcare Conference
▲Topline ReadoutPedmarkApprovedClinical Data
Positive topline results from STS-J01 study of PEDMARK in Japan
cisplatin-induced ototoxicity in pediatric and AYA patients with non-metastatic solid tumorssource ↗
▲Primary Endpoint MetPedmarkApprovedClinical Data
Primary endpoint met in STS-J01 study
cisplatin-induced ototoxicity in pediatric and AYA patients with non-metastatic solid tumorssource ↗
▲Trial InitiationPedmarkApprovedTrial
City of Hope initiated study evaluating PEDMARK for prevention of cisplatin-induced ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors
testicular germ cell tumorssource ↗
▲Topline ReadoutPedmarkApprovedClinical Data
Positive topline results from Phase 2/3 STS-J01 trial in Japan evaluating PEDMARK for reduction of cisplatin-induced ototoxicity in pediatric and AYA patients
non-metastatic solid tumorssource ↗
▼Equity OfferingCorporate
Closing of non-brokered private offering of common shares in Canada for gross proceeds of US$5,025,000
▼Equity OfferingCorporate
Closing of underwritten public offering of 5,366,667 common shares at $7.50 per share for gross proceeds of $40.25 million
◆Topline ReadoutPedmarkApprovedClinical Data
Japan clinical trial STS-J01 preliminary results expected
cisplatin-induced ototoxicitysource ↗
▲Product LaunchPEDMARQSIApprovedPost-Market
Initial uptake of PEDMARQSI in UK and Germany
cisplatin-induced ototoxicitysource ↗
◆Topline ReadoutClinical Data
Japan clinical trial STS-J01 results expected
cisplatin-induced ototoxicitysource ↗
Past FDA Catalysts and PDUFA Decisions
How FENC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | PEDMARK (sodium thiosulfate injection) | Phase 2/3 data readout | Phase 2/3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$7M
Pipeline Value
$137M
Commercial Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 73%
Micro Cap(rank 481 of 658)
Percentile Rank
Fennec Pharmaceuticals Inc. faces pipeline headwinds (29/100), with $18M risk-adjusted pipeline value, led by ADH-1 in Ampulla of Vater Adenocarcinoma (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026; product lines from the latest annual filing) Revenue $59.2M x 2.3 = $137M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| PEDMARK | $45M | $30M | +50.9% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every FENC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PEDMARK® Orphan | reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult patients with non-metastatic solid tumors | Phase 2 | 2026-09-17 | 24.0% (6/25) of patients experienced ASHA-defined hearing loss; historical benchmark of 56.4% (P=0.001); 84.0% of patients had Grade 0 hearing loss; 95.8% objective response rate among evaluable patientsRead More | Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brughera Marco MariaDirector | Option | 15,545 15,545 held | $2.11 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FENC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.1 % | 3.13 M | 334.59 K | 1,530.01% ( 314.07 K) |
FENC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FENC ranks across every disease it competes in
Competitive Position is a premium feature
See how FENC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFENC News
FENCFennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Fennec Pharmaceuticals presented positive results from the Phase 2 STS-J01 clinical trial of PEDMARK® at the SIOP 2026 meeting. The trial demonstrated a significant reduction in cisplatin-induced hearing loss, with only 24% of patients experiencing hearing impairment, compared to a historical benchmark of 56.4%. Additionally, a 95.8% objective response rate was noted among evaluable patients, supporting the efficacy of PEDMARK® in pediatric cancer treatment.
Read more →FENC▲ +16.8%on this news
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported a strong financial performance for the second quarter of 2026, with net product sales reaching $17.1 million, a 78% increase compared to the previous year. The company achieved a non-GAAP adjusted EBITDA of $2.8 million. Additionally, record demand for PEDMARK® is expected to continue into the third quarter, supported by ongoing field sales expansion efforts.
Read more →FENCFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Fennec Pharmaceuticals Inc. will announce its second quarter 2026 financial results on August 11, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company is known for its commitment to reducing ototoxicity in cancer patients through its product PEDMARK, which has received various regulatory approvals.
Read more →FENC▲ +5.2%on this news· ran to +16% by day 3
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fennec Pharmaceuticals has announced the grant of incentive stock options to a new employee as part of its 2026 Equity Inducement Plan. The options, totaling 15,000 shares, were approved by the Compensation Committee and are intended to attract new talent. The exercise price is set at $9.06 per share, aligning with recent market values. Fennec continues to focus on its product PEDMARK® to combat ototoxicity in cancer patients.
Read more →FENCFennec Announces Results of Annual Meeting
Fennec Pharmaceuticals Inc. held its Annual General and Special Meeting of Shareholders on June 10, 2025, announcing the election results of its board nominees. Notably, nearly all nominees received significant approval rates, with Dr. Khalid Islam achieving 97.84% of votes in favor. Shareholders also showed strong support for appointing auditors and approving executive compensation. The meeting addressed amendments to the Company’s 2020 Equity Incentive Plan, utilizing a TSX exemption for smoother execution.
Read more →FENCFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced new research on PEDMARK® at the 2026 ASCO Annual Meeting, highlighting its potential benefits for diverse patient populations. The studies demonstrate that PEDMARK® can be safely integrated into treatment regimens without compromising the efficacy of cisplatin. Results indicate significant reductions in cisplatin-induced hearing loss, particularly among pediatric and adolescent patients. The ongoing research reflects a commitment to addressing unmet needs in cancer survivorship.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) Research Triangle Park, NC
Fennec Pharmaceuticals has announced the grant of stock options to three new non-executive employees as an inducement under Nasdaq Listing Rule 5635(c)(4). The stock options, totaling 50,000 shares, are part of the company's 2026 Equity Inducement Plan, which aims to attract individuals who were not previously employees. Fennec continues to focus on its product PEDMARK, designed to combat ototoxicity in cancer patients, having achieved recent regulatory approvals in multiple regions.
Read more →FENC▲ +36.5%on this newsshared move
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported strong first-quarter financial results for 2026, with net revenues reaching $15.1 million, up 73% year-over-year. The company noted promising early trends from its field sales expansion and highlighted record demand for its product, PEDMARK, in April 2026. Additionally, Fennec has initiated a third clinical study evaluating PEDMARK in adolescent, young adult, and adult patients with head and neck and testicular cancers. Furthermore, four abstracts regarding PEDMARK will be presented at the 2026 ASCO Annual Meeting.
Read more →FENCFENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 14, 2026
Fennec Pharmaceuticals Inc. will announce its first quarter 2026 financial results on May 14, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company focuses on reducing ototoxicity in cancer patients through its FDA-approved product, PEDMARK.
Read more →FENCFennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Fennec Pharmaceuticals Inc. will announce its first quarter 2026 financial results on May 14, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company is focused on its product PEDMARK, which has received several regulatory approvals to combat ototoxicity in cancer patients.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES ACCEPTANCE of ABSTRACTS at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced the acceptance of four abstracts related to PEDMARK® at the 2026 ASCO Annual Meeting. These studies focus on the prevention of cisplatin-induced hearing loss in pediatric and young adult cancer patients. PEDMARK® is FDA-approved for reducing ototoxicity associated with cisplatin treatment, highlighting its significance in improving patient outcomes.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES ACCEPTANCE of ABSTRACTS at the 2026 ASCO Annual Meeting - Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Imp
Fennec Pharmaceuticals announced that four abstracts concerning their PEDMARK treatment have been accepted for the 2026 ASCO Annual Meeting. PEDMARK is designed to prevent cisplatin-induced hearing loss among pediatric and young adult cancer patients. The accepted studies highlight the increasing clinical interest in tackling ototoxicity associated with cisplatin chemotherapy. This follows the FDA approval of PEDMARK, which represents a significant advancement in protective treatments for patients undergoing such therapies.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED STUDY to be Conducted by University of Arizona Cancer Center
Fennec Pharmaceuticals has announced a new investigator-sponsored study by the University of Arizona Cancer Center to evaluate the efficacy of PEDMARK in AYA and adult patients with solid tumors receiving cisplatin. This study aims to explore the drug's potential in preventing cisplatin-induced ototoxicity. The initiative adds to Fennec's ongoing efforts to expand the use of PEDMARK in various patient populations.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES Investigator-SPONSORED STUDY to be Conducted by University of Arizona Cancer Center ~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK in AYA & Adult Patient
Fennec Pharmaceuticals has announced an investigator-sponsored study by the University of Arizona Cancer Center to evaluate the use of PEDMARK in adolescent and adult patients with solid tumors undergoing cisplatin treatment. This study aims to expand the understanding of PEDMARK's benefits in new patient populations. With previous FDA approval and ongoing independent research, Fennec aims to enhance real-world validation and broader clinical adoption of PEDMARK, which is indicated for reducing the risk of cisplatin-induced ototoxicity.
Read more →FENC▲ +6.6%on this news
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fennec Pharmaceuticals announced the grant of 377,500 incentive stock options to 24 new non-executive employees as part of its 2026 Equity Inducement Plan. The options, priced at $5.77 per share, are intended to attract talent and support the company's growth. Fennec is focused on its product PEDMARK/PEDMARQSI, which has received various regulatory approvals to combat ototoxicity in cancer patients.
Read more →FENC▼ -19.2%on this news
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported strong financial results for Q4 and FY 2025, with net product sales reaching $44.6 million, marking a 50% increase from the previous year. The company achieved record patient enrollments and positive clinical study results for PEDMARK in Japan. Fennec is expanding its clinical data strategy and enhancing its field team to further drive growth.
Read more →FENCFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Fennec Pharmaceuticals Inc. has announced the date for its full year and fourth quarter 2025 financial results, set to be revealed on March 24, 2026. The company will host a conference call and webcast on that day to discuss their financial outcomes and future business strategy. Fennec's product, PEDMARK, which targets ototoxicity in cancer patients, continues to gain traction with recent approvals in multiple regions.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION
Fennec Pharmaceuticals has settled litigation with Cipla regarding the latter's attempt to market a generic version of PEDMARK, a sodium thiosulfate injection. The settlement ensures that Cipla will not enter the market until September 1, 2033, allowing Fennec to maintain exclusivity. PEDMARK is the only FDA-approved therapy aimed at reducing cisplatin-induced ototoxicity in pediatric patients.
Read more →FENCFENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION Research Triangle Park, NC
Fennec Pharmaceuticals has announced a settlement with Cipla Limited and Cipla USA to resolve ongoing patent litigation concerning the generic version of their drug PEDMARK. The settlement stipulates that Cipla will not introduce a generic version of sodium thiosulfate until September 1, 2033, or earlier under specific conditions. This resolution allows Fennec to retain market exclusivity for its FDA-approved therapy aimed at preventing ototoxicity in pediatric patients undergoing cisplatin chemotherapy. The agreement reflects Fennec's ongoing commitment to this critical area in pediatric oncology.
Read more →About Fennec Pharmaceuticals Inc.
HeadquartersPO BOX 13628, RESEARCH TRIANGLE PARK, NC, 27709
BIOPHARMAWATCH ELITE PLUS
Trade the next FENC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime